Sandoz, a Novartis division, is a pioneer and a global leader in biosimilars. We invest in research and development to improve the lives of patients and liberate healthcare resources through increased access to high-quality, affordable biologics.
Sandoz Biosimilar Portfolio and Pipeline
Sandoz has a leading biosimilar pipeline and portfolio in immunology, endocrinology and oncology.
Biologics have revolutionized the treatment and prevention of many disabling and life-threatening diseases. A biosimilar is a follow-on medicine of an existing biologic for which the patent has expired and exclusivity has been lost.
Development of Biosimilars
Analytical, preclinical and clinical pharmacokinetic/pharmacodynamic studies demonstrate that the biosimilar medicine matches the reference medicine.
Information for Patients
Biological medicines (or “biologics”) are innovative treatments that have transformed the lives of millions of patients with many disabling and life-threatening diseases.